Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;7(4):439-455.
doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Richard G Wunderink  1 , Evangelos J Giamarellos-Bourboulis  2 , Galia Rahav  3 , Amy J Mathers  4 , Matteo Bassetti  5 , Jose Vazquez  6 , Oliver A Cornely  7 , Joseph Solomkin  8 , Tanaya Bhowmick  9 , Jihad Bishara  10 , George L Daikos  11 , Tim Felton  12 , Maria Jose Lopez Furst  13 , Eun Jeong Kwak  14 , Francesco Menichetti  15 , Ilana Oren  16 , Elizabeth L Alexander  17 , David Griffith  18 , Olga Lomovskaya  18 , Jeffery Loutit  18 , Shu Zhang  17 , Michael N Dudley  18 , Keith S Kaye  19
Affiliations

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Richard G Wunderink et al. Infect Dis Ther. 2018 Dec.

Abstract

Introduction: Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled trial (TANGO II) was conducted from 2014 to 2017 to evaluate the efficacy/safety of meropenem-vaborbactam monotherapy versus best available therapy (BAT) for CRE.

Methods: A total of 77 patients with confirmed/suspected CRE infection (bacteremia, hospital-acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infection, complicated urinary tract infection/acute pyelonephritis) were randomized, and 47 with confirmed CRE infection formed the primary analysis population (microbiologic-CRE-modified intent-to-treat, mCRE-MITT). Eligible patients were randomized 2:1 to meropenem-vaborbactam (2 g/2 g over 3 h, q8h for 7-14 days) or BAT (mono/combination therapy with polymyxins, carbapenems, aminoglycosides, tigecycline; or ceftazidime-avibactam alone). Efficacy endpoints included clinical cure, Day-28 all-cause mortality, microbiologic cure, and overall success (clinical cure + microbiologic eradication). Safety endpoints included adverse events (AEs) and laboratory findings.

Results: Within the mCRE-MITT population, cure rates were 65.6% (21/32) and 33.3% (5/15) [95% confidence interval (CI) of difference, 3.3% to 61.3%; P = 0.03)] at End of Treatment and 59.4% (19/32) and 26.7% (4/15) (95% CI of difference, 4.6% to 60.8%; P = 0.02) at Test of Cure;.Day-28 all-cause mortality was 15.6% (5/32) and 33.3% (5/15) (95% CI of difference, - 44.7% to 9.3%) for meropenem-vaborbactam versus BAT, respectively. Treatment-related AEs and renal-related AEs were 24.0% (12/50) and 4.0% (2/50) for meropenem-vaborbactam versus 44.0% (11/25) and 24.0% (6/25) for BAT. Exploratory risk-benefit analyses of composite clinical failure or nephrotoxicity favored meropenem-vaborbactam versus BAT (31.3% [10/32] versus 80.0% [12/15]; 95% CI of difference, - 74.6% to - 22.9%; P < 0.001).

Conclusions: Monotherapy with meropenem-vaborbactam for CRE infection was associated with increased clinical cure, decreased mortality, and reduced nephrotoxicity compared with BAT.

Clinical trials registration: NCT02168946.

Funding: The Medicines Company.

Keywords: Best available therapy; Carbapenem-resistant Enterobacteriaceae; Meropenem–vaborbactam; Randomized clinical trial; TANGO II.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow of patients in TANGO II. mCRE-MITT microbiologic-carbapenem-resistant Enterobacteriaceae-modified intent-to-treat, MITT modified intent-to-treat, m-MITT microbiologic modified intent-to-treat; M–V meropenem–vaborbactam, VABP ventilator-associated bacterial pneumonia. aBest available therapy included (alone or in combination): a carbapenem, aminoglycoside, polymyxin B, colistin, tigecycline, or (monotherapy only) ceftazidime-avibactam
Fig. 2
Fig. 2
Subgroup analysis. mCRE-MITT microbiologic carbapenem-resistant Enterobacteriaceae modified intent-to-treat, SIRS systemic inflammatory response syndrome
See this image and copyright information in PMC

References

    1. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017 doi: 10.1007/s00134-017-4878. - DOI - PubMed
    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. https://www.cdc.gov/drugresistance/threat-report-2013/index.html. Accessed 27 Aug 2017.
    1. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http://www.who.int/medicines/publications/global-priority-list-antibioti.... Accessed 5 Sep 2017.
    1. European Commission. A European One Health action plan against antimicrobial resistance (AMR). https://ec.europa.eu/health/amr/action_eu_en. Accessed 5 Sep 2017.
    1. The Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics. http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2013/11/0.... Accessed 5 Sep 2017.

Associated data